| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H34O6 |
| Molecular Weight | 406.5125 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(=O)O3)OC(=O)[C@@H](C)CC
InChI
InChIKey=OQARDMYXSOFTLN-PZAWKZKUSA-N
InChI=1S/C23H34O6/c1-4-13(2)23(27)29-20-11-16(24)9-15-6-5-14(3)19(22(15)20)8-7-18-10-17(25)12-21(26)28-18/h5-6,9,13-14,16-20,22,24-25H,4,7-8,10-12H2,1-3H3/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
| Molecular Formula | C23H34O6 |
| Molecular Weight | 406.5125 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Pravastatin Lactone is a metabolite of pravastatin. Pravastatin is HMG-CoA reductase inhibitor and it is primarily used for the treatment of dyslipidemia and the prevention of cardiovascular disease. Pravastatin and pravastatin-lactone uptake is liver cell specific. Pravastatin-lactone uptake into isolated rat liver cells is carrier mediated. The mutual competitive transport inhibition of bile acids and pravastatin and pravastatin-lactone in sodium-free medium indicates that these compounds share a common transport system. Pravastatin lactone, based on its lipophilicity, showed a high myotoxic potential.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
